Atypical Central Neurocytoma

• Published in: Journal of neuropathology and experimental neurology 1997-05, Vol.56 (5), p.551-556
• Main Authors: SÖYLEMEZOGLU, FIGEN, SCHEITHAUER, BERND W, ESTEVE, JACQUES, KLEIHUES, PAUL
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Biological and medical sciences; Biopsy; Cerebral Ventricle Neoplasms - blood supply; Cerebral Ventricle Neoplasms - metabolism; Cerebral Ventricle Neoplasms - pathology; Child; Comparative analysis; Female; Humans; Immunohistochemistry; Male; Medical sciences; Middle Aged; Monoclonal antibodies; Neoplasm Recurrence, Local; Neovascularization, Pathologic - pathology; Neurocytoma - blood supply; Neurocytoma - metabolism; Neurocytoma - pathology; Neurology; Survival Analysis; Tumors of the nervous system. Phacomatoses
• ISSN: 0022-3069; 1554-6578
• DOI: 10.1097/00005072-199705000-00011

The proliferative potential of central neurocytomas was determined in a biopsy series of 36 cases and compared with clinical outcome. The mean size of the growth fraction, as determined by MIB-1 labeling index (MIB-1 LI) at first biopsy, was 2.8 ± 2.5 with a range of 0.1 to 8.6%. Neurocytomas with an MIB-1 LI >2% comprised 39% of cases and showed a close correlation with the presence of vascular proliferation (p = 0.0006). The Kaplan-Meier analysis showed a highly significant difference in disease-free survival between the 2 groups (p =0.0068). Over an observation time of 150 months, there was a 22% relapse among patients with an MIB-1 LI less than 2% and a 63% chance of relapse among those with an MIB-1 LI greater than 2%. We propose the term “atypical central neurocytoma” for the latter subset, corresponding to WHO grade II.